Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
08/10/2017 08/11/2017 08/14/2017 08/15/2017 08/16/2017 Date
57.49(c) 56.82(c) 57.45(c) 57.5(c) 57.95 Last
339 605 269 149 279 338 240 701 321 637 Volume
-0.02% -1.17% +1.11% +0.09% +0.78% Change
More quotes
Financials (€)
Sales 2017 4 334 M
EBIT 2017 950 M
Net income 2017 604 M
Debt 2017 565 M
Yield 2017 2,08%
Sales 2018 4 529 M
EBIT 2018 1 087 M
Net income 2018 714 M
Debt 2018 51,9 M
Yield 2018 2,22%
P/E ratio 2017 17,12
P/E ratio 2018 14,67
EV / Sales2017 2,71x
EV / Sales2018 2,48x
Capitalization 11 184 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
09/06Presentation
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
08/03 UCB : Reports Summarize Parkinson's Disease Study Results from UCB S.A. (U18666A..
08/03 UCB : S.A. - Transparency notification The Capital Group Companies
08/03 UCB : Transparency Notification the Capital Group Companies
07/27 UCB : Amgen And UCB Provide Update On Regulatory Status Of EVENITY romosozumab I..
07/27 UCB : with a strong first half year 2017 – giving rise …
07/25 UCB : and Dermira Announce U.S. and EU Regulatory Submissions …
07/24 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP …
07/21 UCB : Bimekizumab Demonstrates Skin Clearance in Phase 2b Psoriasis Study with &..
07/16 UCB : and Amgen Provide Update on Regulatory Status of EVENITY …
07/06 UCB : Study Findings on Clinical Pharmacology Are Outlined in Reports from UCB S..
More news
Sector news : Pharmaceuticals - NEC
08/15DJWal-Mart CEO Criticizes Trump's Virginia Response
08/15DJTwo More Corporate Executives Quit Trump Advisory Council
08/15DJCSL : Says Net Profit Rises On Immunoglobulin, Specialty-Product Sales
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker -2-
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker Stumbles When Customers Balk
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on UCB 
08/09Close to a key level on the weekly chart
04/07There is still some upside potential
More Strategies
Latest Tweets
08/03MRC links with UCB in antibody initiative  
07/27Briefing actions (27 juillet) - AB InBev, UCB, bpost, Ontex, Aperam, Cofinimm.. 
07/27UCB : with a strong first half year 2017 – giving rise ….. 
07/25Briefing actions (25 juillet) - GBL, UCB, Aperam, Ageas, Telenet, Ahold Delha.. 
07/25UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (cert.. 
More tweets
Qtime:51
News from SeekingAlpha
07/31 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
07/17 FDA rejects Amgen's marketing application for osteoporosis candidate romosozu..
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 66,1 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-5.60%13 129
JOHNSON & JOHNSON15.77%357 240
ROCHE HOLDING LTD.5.07%217 697
NOVARTIS9.99%217 255
PFIZER2.77%198 008
MERCK AND COMPANY6.17%170 132